The Syngene Journey

Since our inception, we have made significant investments in our capacity and capabilities across the drug discovery, development and manufacturing value chain. This strategy has enabled us build collaborative, long-term relationships with our clients and deliver better value to all our stakeholders.

1993

Initiated operations as a CRO with services in chemistry and biology

Granted 100% Export-Oriented Unit (EOU) status by the Government of India

1998

1999

Achieved first operational expansion in R&D with lab space increased to over 23,000 sq. ft.

Forayed into Chemical Development with a dedicated manufacturing facility

2001

2003

Moved to Biocon SEZ, a 90-acre biopharmaceutical SEZ with operations spread over 65,000 sq. ft.

Signed a contract with Bristol-Myers Squibb for setting up our first dedicated R&D centre

Expanded research laboratory infrastructure to 148,000 sq. ft.

Crossed an annual turnover of Rs. 1,000 Mn

2007

2009

Expanded manufacturing services with a new cGMP (Current Good Manufacturing Practices) plant

Initiated operations in Safety Assessment Services, Formulation Development and Biologics Development Services

Collaboration with Endo Pharmaceuticals, USA to develop novel biological therapeutic molecules against cancer

2011

2012

Established Abbott’s first nutrition R&D centre in India

Received ANVISA Certification for clinical facilities

Acquired 100% stake in Clinigene International Limited, a clinical research company

Crossed an annual turnover of Rs. 5,000 Mn

Established dedicated R&D centre for Baxter International Inc.

Syngene Control Testing Laboratory accepted by the Department of Health & Human Services, USFDA

2013

2014

Extended collaboration with Bristol-Myers Squibb for its dedicated R&D centre till 2020

Syngene API manufacturing facility accepted by the Department of Health & Human Services, USFDA

Established a 75,000 sq. ft. centre to provide stability and analytical services

Syngene listed on BSE (Bombay Stock Exchange) and NSE (National Stock Exchange) of India

Clinigene International, amalgamated with Syngene

2015

2016

Acquired Strand Life Sciences’ Systems Biology and Pharma Services Practice Assets: Expanded into Bioinformatics and NGS Services

Established dedicated R&D centre for Amgen Inc.

Crossed an annual turnover of Rs. 10,000 Mn

Strategic collaboration with Zoetis to develop and manufacture animal medicines

Collaborated with Herbalife to establish its first nutrition R&D centre in India

Broadened research collaboration with Amgen Inc., leading to expansion of facilities

Extended contract with Bristol-Myers Squibb till 2026

2017

2018

Signed R&D agreement with GSK to advance drug discovery in multiple therapeutic areas

Received PMDA Accreditation

Expanded collaboration with Baxter International Inc. till 2024

Signed an agreement with Biotechnology Industry Research Assistance Council (BIRAC), a Government of India undertaking, for setting up Centre for Advanced Protein Studies (CAPS)

2019